{"created":"2023-07-27T06:29:59.802128+00:00","id":14831,"links":{},"metadata":{"_buckets":{"deposit":"62c1a5ad-56a9-4e94-b40a-fb0a19b3a991"},"_deposit":{"created_by":3,"id":"14831","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14831"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014831","sets":["1132:1133:1135"]},"author_link":["26568","26567","26569","26566","26564","531","26565"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2006-01-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"3","bibliographicPageEnd":"173","bibliographicPageStart":"168","bibliographicVolumeNumber":"59","bibliographic_titles":[{"bibliographic_title":"Japanese Journal of Infectious Diseases"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The prevalence of adult HIV/AIDS in Thailand is declining due to intense prevention strategies, but it still continues to be a critical health problem with a prevalence of 1.5%. Several HIV vaccine candidates for the prevention of HIV infection or progress to AIDS were examined in clinical trials. We evaluated the cost-effectiveness of a vaccination regimen (rBCG prime-rDIs boost) currently in its pre-clinical phase. The cost-effectiveness of three interventions (vaccination, highly active antiretroviral treatment [HAART], and the combination of the two) through an existing vaccination program was assessed in a Markov model. The disability-adjusted life year (DALY) was the main effectiveness measure. In the base case the efficacy of the vaccine for preventing HIV infection was assumed to be 30%. The cost of the vaccine was estimated on the basis of its predicted production capacities in Thailand. The incremental cost-effectiveness ratios of vaccination, HAART, and the combination were about $US 75, $US 610, and $US 267 per DALY averted compared with the do-nothing strategy in the base case. The HAART-only strategy seemed to be less cost-effective than the other options under the current assumptions. Sensitivity analyses indicated that the new HIV infection rate and the vaccine efficacy could affect the results.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"東京大学大学院薬学系研究科 医薬品評価科学講座","subitem_description_type":"Other"},{"subitem_description":"元・金沢大学大学院自然科学研究科","subitem_description_type":"Other"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"国立感染症研究所"}]},"item_4_publisher_19":{"attribute_name":"出版者（別名）","attribute_value_mlt":[{"subitem_publisher":"National Institute of Infectious Diseases"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1344-6304","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ono, Shunsuke"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"Kurotani, Takako"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakasone, Tadashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Honda, Mitsuo"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Boon-Long, Jotika"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Sawanpanyalert, Pathom"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"木村, 和子"}],"nameIdentifiers":[{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-ONO-S-168.pdf","filesize":[{"value":"76.8 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-ONO-S-168.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14831/files/ME-PR-ONO-S-168.pdf"},"version_id":"d60ecf74-c9e3-40d7-8c8a-e7aaf67d55d0"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand"}]},"item_type_id":"4","owner":"3","path":["1135"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14831","relation_version_is_last":true,"title":["Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-07-27T09:44:27.114362+00:00"}